Pfisterer J - Search Results

1

Future options for first-line therapy of advanced ovarian cancer.

Du Bois A, Pfisterer J. Du Bois A, et al. Among authors: pfisterer j. Int J Gynecol Cancer. 2005 May-Jun;15 Suppl 1:42-50. doi: 10.1111/j.1525-1438.2005.15356.x. Int J Gynecol Cancer. 2005. PMID: 15839958 Free article. Review.

2

Cellular DNA content and survival in advanced ovarian carcinoma.

Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, Pfleiderer A. Pfisterer J, et al. Cancer. 1994 Nov 1;74(9):2509-15. doi: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f. Cancer. 1994. PMID: 7923008

3

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.

du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall P, Pfisterer J, Bauknecht T. du Bois A, et al. Among authors: pfisterer j. J Cancer Res Clin Oncol. 1994;120(3):173-8. doi: 10.1007/BF01202198. J Cancer Res Clin Oncol. 1994. PMID: 8263015 Clinical Trial.

4

First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.

du Bois A, Lück HJ, Bauknecht T, Meier W, Richter B, Kuhn W, Quaas J, Pfisterer J. du Bois A, et al. Among authors: pfisterer j. J Clin Oncol. 1999 Jan;17(1):46-51. doi: 10.1200/JCO.1999.17.1.46. J Clin Oncol. 1999. PMID: 10458217 Clinical Trial.

5

[Anthracyclines in therapy of ovarian carcinoma: a systematic review of primary and 2nd-line therapy after platinum].

du Bois A, Lück HJ, Pfisterer J, Meier W, Bauknecht T. du Bois A, et al. Among authors: pfisterer j. Zentralbl Gynakol. 2000;122(5):255-67. Zentralbl Gynakol. 2000. PMID: 10857212 Review. German.

6

The integration of anthracyclines in the treatment of advanced ovarian cancer.

Lück HJ, Du Bois A, Weber B, Pfisterer J, Goupil A, Kuhn W, Barats JC, Blohmer J, Mousseau M, Schröder W, Meier W, Möbus V, Richter B; AGO-GINECO Intergroup. Lück HJ, et al. Among authors: pfisterer j. Int J Gynecol Cancer. 2001;11 Suppl 1:34-8. Int J Gynecol Cancer. 2001. PMID: 11489001

7

Second-line carboplatin and gemcitabine in platinum sensitive ovarian cancer--a dose-finding study by the Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) Ovarian Cancer Study Group.

du Bois A, Lück HJ, Pfisterer J, Schroeder W, Blohmer JU, Kimmig R, Moebus V, Quaas J. du Bois A, et al. Among authors: pfisterer j. Ann Oncol. 2001 Aug;12(8):1115-20. doi: 10.1023/a:1011605008922. Ann Oncol. 2001. PMID: 11583193 Free article.

8

State-of-the-art first-line treatment of ovarian cancer.

Pfisterer J, Hilpert F, Du Bois A, Meier W, Wagner U. Pfisterer J, et al. Onkologie. 2003 Oct;26(5):446-50. doi: 10.1159/000072977. Onkologie. 2003. PMID: 14605460 Review.

9

Improving first-line therapy of advanced ovarian cancer - the AGO Ovarian Cancer Study Group perspective.

du Bois A, Pfisterer J, Meier W, Wagner U. du Bois A, et al. Among authors: pfisterer j. Int J Gynecol Cancer. 2003 Nov-Dec;13 Suppl 2:169-71. doi: 10.1111/j.1525-1438.2003.t01-2-13352.x. Int J Gynecol Cancer. 2003. PMID: 14656275

10

[First-line therapy in ovarian cancer].

du Bois A, Pfisterer J. du Bois A, et al. Among authors: pfisterer j. Zentralbl Gynakol. 2004 Oct;126(5):312-4. doi: 10.1055/s-2004-820390. Zentralbl Gynakol. 2004. PMID: 15478049 Review. German.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

207 results

Search Page

Filters